Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic

2014 ◽  
Vol 44 (4) ◽  
pp. 345-353 ◽  
Author(s):  
M. J. Carrington ◽  
Y.-K. Chan ◽  
S. Stewart ◽  
B. Sjouke ◽  
R. Brazilek ◽  
...  
2018 ◽  
Vol 46 (6) ◽  
pp. 608-615 ◽  
Author(s):  
Andre Ma ◽  
Martin SY Mak ◽  
Kendrick Co Shih ◽  
Claudia KY Tsui ◽  
Rachel KY Cheung ◽  
...  

2020 ◽  
Vol 2 (9) ◽  
pp. 496-502
Author(s):  
Hannah Syed

Intensive treatment with insulin and sulfonylureas in older people with low HbA1c (<53mmol/mol) can increase the risk of hypoglycaemia, morbidity and mortality. Older people, particularly those with frailty and/or comorbidities are less likely to benefit from the long-term protective effects of good glycaemic control and are often at risk of inappropriate polypharmacy. A person-centred holistic approach to diabetes management must be adapted for older people living with diabetes.


2017 ◽  
Vol 35 (2) ◽  
pp. 243-253 ◽  
Author(s):  
Annunziata Lapolla ◽  
◽  
Cesare Berra ◽  
Massimo Boemi ◽  
Antonio Carlo Bossi ◽  
...  

Author(s):  
Saajid Hameed ◽  
Pankaj Kumar ◽  
Ved Prakash ◽  
Manish Kumar ◽  
Harihar Dikshit

Introduction: Insulin therapy is preferred as safest for glycaemic control in patients with elevated serum urea/creatinine level. Management of diabetes in grade 3-5 Chronic Kidney Disease (CKD) with oral hypoglycaemic is very challenging because most of them cause renal impairment and thus dose adjustment is needed in renal disease. Linagliptin, a DPP-4 (dipeptidyl peptidase-4) inhibitor has only 5% renal excretion; hence its dose adjustment is not needed in patients with CKD. Aim: To compare the efficacy and safety of linagliptin with insulin in patients of Type 2 Diabetes Mellitus (T2DM) with CKD. Materials and Methods: The present study was a longitudinal study, in which a total of 101 patients of grade 3-5 CKD with T2DM were divided into two groups, insulin group (n=54) and linagliptin group (n=47), based on their drug therapy. All the cases were tested for HbA1c (Glycated Haemoglobin), Random Blood Sugar (RBS), Creatinine clearance, Urine Protein-Creatinine Ratio (UPCR) and different adverse drug events at their first visit (baseline) and then during follow-up at 1st, 3rd, 6th and 12th month. Statistical analysis was done through GraphPad Instat by unpaired t-test for group comparison and Analysis of Variance (ANOVA) for intragroup comparison. Results: At the end of study, mean difference of RBS, Creatinine clearance and UPCR in both the groups were not significant. But mean HbA1c level was less in linagliptin group (6.62±0.10) as compared to insulin group (6.82±0.23) on long term therapy and the difference was statistically significant. Hypoglycaemia (33 vs 24), urinary tract infection (6 vs 5) and respiratory tract infection (5 vs 4) were more frequent in insulin group versus linagliptin group. Conclusion: Linagliptin for glycaemic control provides clinically meaningful improvements in long term glycaemic control without unacceptable side effects in CKD like vulnerable group of patients.


Sign in / Sign up

Export Citation Format

Share Document